Skip to Content

Tenecteplase Boehringer Ingelheim Pharma GmbH & Co. KG

Active Substance: tenecteplase
Common Name: tenecteplase
ATC Code: B01AD
Marketing Authorisation Holder: Boehringer Ingelheim International GmbH
Active Substance: tenecteplase
Status: Withdrawn
Authorisation Date: 2001-02-23
Therapeutic Area: Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Tenecteplase Boehringer Ingelheim Pharma GmbH & Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.

The marketing authorisation for Tenecteplase Boehringer Ingelheim Pharma GmbH & Co. KG has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide